Hematology Frontier

In early September 2024, the 5th Tianjin International Lymphoma Conference was held from September 6 to 8, amid the golden season of autumn. This conference featured 12 specialized sessions, including immunotherapy, basic translational research, and new drug development, creating a high-end academic platform for international exchange and collaboration. During the event, Hematology Frontier invited Dr. Jianxiang Wang from the Institute of Hematology & Blood Diseases Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College to provide an in-depth analysis of the current state and future trends of CAR-T cell therapy in China from his academic perspective.

From September 6 to 8, 2024, the 5th Tianjin International Lymphoma Conference was successfully held. The conference featured 12 specialized sessions, including immunotherapy, translational research, and new drug development, creating a platform for international academic exchange and cooperation. During the event, Hematology Frontier invited Dr. Wei Sang from The Affiliated Hospital of Xuzhou Medical University to provide an in-depth analysis of CAR-T cell therapy in different hematologic malignancies and explore strategies for optimizing treatment outcomes.

The 12th Annual Meeting of the Society of Hematologic Oncology (SOHO 2024) took place in Houston, USA, from September 4 to 7, 2024. It brought together leading experts in hematologic oncology from around the world to discuss the latest research findings and explore new treatment strategies. Among the numerous topics discussed, the treatment of T-cell acute lymphoblastic leukemia (T-ALL) and lymphoblastic lymphoma (T-LBL) was a focal point due to the high relapse rate and treatment complexity associated with these diseases. Traditional treatments often fail to provide long-term remission, and CAR-T cell therapy faces the challenge of inadvertently targeting healthy T-cells, further complicating treatment.

With the rapid advancements in medical technology and deeper insights into the mechanisms of lymphoma, traditional chemotherapy is gradually giving way to a new era of precision-targeted and immunotherapies. Innovative drugs are emerging like bamboo shoots after the rain, offering personalized treatment paths tailored to lymphoma patients. This marks the dawn of a new era in disease management, with the promise of more effective and optimistic treatment outcomes. At the 12th Lu Daopei Hematology Forum, Hematology Frontier invited Dr. Hongmei Jing from Peking University Third Hospital to provide a comprehensive analysis of the current state of lymphoma treatment in China, explore future research directions, and discuss the field's ongoing development.

The 50th Annual Meeting of the European Society for Blood and Marrow Transplantation (EBMT) was held from April 14th to 17th in Glasgow, United Kingdom, showcasing the latest advancements in stem cell transplantation and cell therapy. These advancements are driving better clinical outcomes for patients with hematological diseases and blood cancers. At this year's conference, two studies conducted by Professor Xiaoyan Ke from Peking University Third Hospital/Beijing Chaoyang Hospital and Professor Kai Hu from Beijing Chaoyang Hospital were presented, highlighting how combined autologous hematopoietic stem cell transplantation and CAR-T cell therapy can improve survival rates for lymphoma and multiple myeloma patients.

Multiple Myeloma (MM) is a common hematologic malignancy, and with the emergence of immunotherapy, particularly CAR-T therapy as a revolutionary immunotherapeutic approach, the survival of patients with relapsed/refractory multiple myeloma (R/R MM) has significantly improved. From April 14th to 17th, 2024, the 50th Annual Meeting of the European Society for Blood and Marrow Transplantation (EBMT) was held in Glasgow, United Kingdom, focusing on the latest advancements in stem cell transplantation and cell therapy, driving towards better clinical outcomes for hematologic disease patients. At this conference, Professor Chunrui Li from Tongji Hospital affiliated with Huazhong University of Science and Technology School of Medicine in China presented a study comparing the efficacy of five currently available BCMA-targeting CAR-T cell products, attracting widespread attention. In this exclusive interview, Professor Chunrui Li shares the main findings of the study and provides insightful interpretations of the latest research advancements in CAR-T cell therapy for R/R MM.

Graft failure is a rare but fatal complication following haploidentical allogeneic hematopoietic stem cell transplantation. A second transplant is almost the only salvage measure for transplant failure. However, outcomes from second transplants have generally been poor, as reported in previous literature. The 50th European Society for Blood and Marrow Transplantation (EBMT) annual meeting was held in Glasgow, UK, from April 14th to 17th, 2024. The conference focused on the latest advancements in stem cell transplantation and cellular therapy, driving better clinical outcomes for patients with blood disorders. At this conference, a team led by Professor Yuqian Sun from Peking University People's Hospital presented their findings in an oral report titled "Salvage Haploidentical Transplantation with Flu/Cy Regimen and Donor Switching After Primary Graft Failure: Follow-Up Results," which garnered significant attention. Professor Sun was invited to share the main results of this study and the progress in salvage treatments for graft failure after haploidentical allogeneic hematopoietic stem cell transplantation.

The 29th Annual Meeting of the European Hematology Association (EHA) was grandly held in Madrid, Spain, from June 13 to 16, 2024. At this EHA conference, a study (S200) by Professors Juan Du and Jing Lu from Shanghai Changzheng Hospital was selected for an oral presentation. This study explored the efficacy and safety of GC012F in the first-line treatment of newly diagnosed high-risk multiple myeloma patients eligible for transplantation. To discuss the study and the treatment of multiple myeloma, "Oncology Frontier - Hematology Frontier" conducted an interview with Professor Jing Lu.

From June 13th to 16th, 2024, the 29th Annual Meeting of the European Hematology Association (EHA) was grandly held in Madrid, the capital of Spain. As the largest international conference in the field of hematology in Europe, it attracts experts and scholars from all over the world each year to share and discuss innovative concepts and the latest scientific and clinical research achievements in hematology. At this year's EHA conference, several studies from Professor Xufan Zhu's team at the Institute of Hematology & Blood Diseases Hospital, Chinese Academy of Medical Sciences were selected. This issue highlights two studies on pediatric bone marrow failure diseases (acquired aplastic anemia and Shwachman-Diamond syndrome) and includes insightful commentary from Professor Zhu.

The 29th Annual Meeting of the European Hematology Association (EHA) was grandly held in Madrid, Spain, from June 13 to 16, 2024. At this EHA conference, a study (S200) by Professors Juan Du and Jing Lu from Shanghai Changzheng Hospital was selected for an oral presentation. This study explored the efficacy and safety of GC012F in the first-line treatment of newly diagnosed high-risk multiple myeloma patients eligible for transplantation. To discuss the study and the treatment of multiple myeloma, "Oncology Frontier - Hematology Frontier" conducted an interview with Professor Jing Lu.